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Communicated by Jürgen Horst 
Nephronophthisis (NPH), a recessive cystic kidney disease, is the most frequent genetic cause 
for end-stage renal disease in the first two decades of life. Mutations in three genes (NPHP1, 
2, and 3) were identified as causative. Extrarenal manifestations are known, such as retinitis 
pigmentosa (Senior-Løken syndrome, SLS) and ocular motor apraxia type Cogan. Recently, 
we identified a novel gene (NPHP4) as mutated in NPH. To date, a total of only 13 different 
NPHP4 mutations have been described. To determine the frequency of NPHP4 mutations, 
we performed mutational analysis by direct sequencing of all 30 NPHP4 exons in 250 
different patients with isolated NPH, SLS, or Cogan syndrome ascertained worldwide over 
14 years. We identified 23 novel NPHP4 sequence variants in 26/250 different patients 
(10%). Interestingly, we detected homozygous or compound heterozygous mutations of 
NPHP4 in only 6/250 different patients (2.4%), but only one heterozygous NPHP4 sequence 
variant in 20/250 different patients (8%). In the six patients with two NPHP4 mutations, 5/8 
mutations (63%) were likely loss-of-function mutations, whereas in the 20 patients with only 
one sequence variant, only 1/20 (5%) was a likely loss-of-function (i.e., truncating) mutation. 
We conclude that: i) two recessive mutations in NPHP4 are a rare cause of 
nephronophthisis; ii) single heterozygous NPHP4 sequence variants are three times more 
prevalent than two recessive mutations; iii) there is no genotype/phenotype correlation; iv) 
there must exist further genes causing nephronophthisis, since in 224/250 (90%) patients, no 
sequence variants in either of the four NPH genes were detected. © 2005 Wiley-Liss, Inc. 
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INTRODUCTION 
Nephronophthisis (NPH) is an autosomal recessive cystic kidney disease that represents the most common genetic 
cause for end-stage renal disease in children and young adults (Hildebrandt et al., 2001). NPH leads to end-stage 
renal disease at a median age of 13 years. Characteristic renal histology shows a triad of renal interstitial fibrosis, 
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interstitial cell infiltrates, and tubular atrophy with cyst development at the corticomedullary junction (Waldherr et 
al., 1982). NPH is a genetically heterogenous disorder. Four genes have been identified: Recessive mutations in 
NPHP1 cause NPH type 1 (juvenile onset) (MIM# 256100) (Hildebrandt et al., 1997, Saunier et al., 1997). Its gene 
product nephrocystin (NPHP1) is a novel docking protein that plays a role in signaling at adherens junctions and 
focal adhesions of renal epithelial cells. Mutations in the NPHP2 gene encoding inversin cause NPH type 2 
(infantile onset) (MIM# 602088) (Haider et al., 1998, Otto et al., 2003). Mutations in NPHP3 and its gene product 
nephrocystin-3 are responsible for NPH type 3 (adolescent form) (MIM# 604387, 608002) (Olbrich et al., 2003, 
Omran et al., 2000). Finally, we have identified mutations in NPHP4 encoding nephrocystin-4/nephroretinin as 
causing NPH type 4 (juvenile onset) (MIM# 607215, 606966, 606996) (Mollet et al., 2002, Otto et al., 2002, 
Schuermann et al., 2002). With the exception of inversin, the NPH-causing genes represent novel genes. Recent 
evidence demonstrated expression of all 4 genes (NPHP1-4) in primary cilia of renal epithelial cells, a feature that 
has been recognized for virtually all proteins which, if defective give rise to renal cystic disease in mice or humans 
(Watnick et al., 2003). The gene products of the NPHP2, 3 and 4 genes bind to nephrocystin, the gene product of 
the NPHP1 gene (Mollet et al., 2002). A number of extrarenal manifestations can be associated with NPH, such as 
retinitis pigmentosa (Senior-Løken syndrome, SLS) (Loken et al., 1961, Senior et al., 1961), ocular motor apraxia 
(Cogan syndrome) (Betz et al., 2000, Mollet et al., 2002), or liver fibrosis (Boichis et al., 1973). Retinitis 
pigmentosa is associated with NPH in about 10% of cases (Caridi et al., 1998). So far no genotype/phenotype 
correlation regarding the type of NPHP gene mutated or regarding distinct mutated alleles of these genes have 
been detected. The recently identified NPHP4 gene extends over 130 kb, consists of 30 exons, and encodes 1426 
amino acids. NPHP4 is strongly conserved in evolution, with 23% amino acid identity in a protein of C. elegans 
(Mollet et al., 2002, Otto et al., 2002). So far only 13 different mutations in NPHP4 have been reported in 17 
different patients (Mollet et al., 2002, Otto et al., 2002). 
To determine the frequency of NPHP4 mutations in a large cohort of patients with NPH, we here performed 
mutational analysis by direct sequencing of all 30 exons of NPHP4 in 250 unrelated NPH patients. We identified 
23 novel NPHP4 sequence variants in 26 unrelated patients with NPH. We detected both recessive mutations of 
NPHP4 in only 6/250 different patients (2.4%), whereas we detected only one heterozygous NPHP4 sequence 
variant in 20/250 different patients. From these data we conclude, i) mutations in NPHP4 are a rare cause (2.4%) 
of nephronophthisis; ii) there is no genotype/phenotype relationship regarding extrarenal manifestations; iii) there 
must exist further genes causing nephronophthisis. 
 
PATIENTS AND METHODS 
Patients 
For mutation screening in NPHP4 we selected from a cohort of 375 patients with NPH on the basis of DNA 
availability 250 unrelated patients with at least one child affected by isolated NPH, SLS or Cogan syndrome. The 
diagnostic criteria were as follows: i) characteristic clinical phenotype of NPH, SLS or Cogan syndrome, as 
established by a pediatric nephrologist using a standard clinical questionnaire (www.renalgenes.org); ii) renal 
ultrasound or a renal biopsy result compatible with NPH; iii) exclusion of a homozygous deletion in NPHP1; iv) 
pedigree compatible with autosomal recessive inheritance. Renal biopsy result was considered characteristic for 
NPH if there was disruption of tubular basement membranes, tubulointerstitial round cell infiltration and fibrosis, 
and tubular atrophy with microcyst development (Waldherr et al., 1982). Renal ultrasound was considered 
characteristic for NPH if there was increased echogenicity with loss of corticomedullary differentiation or presence 
of corticomedullary cysts. Origin of patients was worldwide with an emphasis on European descent. We obtained 
blood samples, pedigrees, and clinical information following informed consent (www.renalgenes.org). To assess 
the genetic data about the frequency of NPHP4 mutations, we evaluated only one sibling per family. This cohort of 
250 unrelated patients consisted of 190 patients with isolated NPH (76%), 50 patients with SLS (20%), and 10 
patients with Cogan syndrome (4%). Consanguinity was present in 9/190 NPH patients (5%), 6/50 SLS patients 
(12%), and in 1/10 patients with Cogan syndrome (10%). The diagnosis of NPH was confirmed by renal biopsy in 
61/190 NPH patients (32%), 4/50 SLS patients (8%), and 1/10 patients with Cogan syndrome (10%). For all 
patients we had previously excluded a homozygous deletion of NPHP1, a combination of a heterozygous NPHP1 
deletion with a heterozygous NPHP1 point mutation, and mutations in NPHP3. The diagnosis of infantile NPHP 
(NPHP2) was excluded by absence of the NPHP2-specific criterion of end-stage renal disease occurring within the 
first 5y of life.  
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Mutational analysis 
Genomic DNA was extracted from blood samples using the QIAGEN Blood & Cell Culture DNA kit according 
to the manufacturer’s instructions (Qiagen, Valencia, CA). For one individual from each family (250 patients) 
direct sequencing was performed for all 30 NPHP4 exons on both strands using the dideoxy chain termination 
method on an ABI capillary sequencer. Resulting sequences were aligned and analyzed with the Sequencher™ 
software (Gene Codes Corporation, Ann Arbor, MI) and Mutation Surveyor™. Primers flanking the 30 exons of 
NPHP4 were derived from genomic sequence, using the program PRIMER3 (http://zeon.well.ox.ac.uk/git-
bin/primer3_www.cgi) (GenBank accession no. NT_015102, which corresponds to the published cDNA and amino 
acid sequences. Numbering is based on cDNA sequence. Position +1 corresponds to the A of the ATG translation 
initiation codon in the reference sequence. Mollet et al., 2002, Otto et al., 2002) . Primer sequences are available 
from the authors. For segregation analyses parental DNA, if available, was tested by direct sequencing. For 
mutational screening of healthy control individuals we employed allele-specific restriction digests, denaturing 
high-performance liquid chromatography (Transgenomic Wave™), or direct sequencing, as appropriate. For all 
patients with sequence variants in NPHP4 direct sequencing was performed for all 17 exons of NPHP2 on one 
strand using the dideoxy chain termination method on an ABI capillary sequencer. 
 
RESULTS 
In a cohort of 250 unrelated patients with NPH, SLS or Cogan syndrome, we performed mutational analysis by 
direct sequencing of both strands for all 30 exons of NPHP4 (a total of 15,000 sequences). We detected altogether 
23 different novel NPHP4 sequence variants in a total of 26/250 unrelated patients (10%) (Table 1). However, in 
only 6/250 families (2.4%) we detected both mutated alleles, i.e. two heterozygous mutations or one homozygous 
mutation of NPHP4 (Table 1). Most mutations were truncating mutations. Both missense mutations detected in 
F720 are conserved in Nphp4 of mouse and nph-4 of C. elegans. In contrast, in 20/250 families (8%) we found 
only a single heterozygous sequence variant of NPHP4 (Table 1). All sequence variants were novel, i.e. they have 
not been reported previously (Mollet et al., 2002, Otto et al., 2002). All mutations were absent from at least 86 
healthy control individuals and were not previously described as polymorphisms (Table 2). A total of 224/250 
(90%) patients did not show any sequence variant in NPHP4. The total of 26 sequence variants consisted of 23 
different novel sequence variants (Table 1). Of the patients, in whom only one sequence variant was found, 4 
patients shared a mutation with at least one other patient (F270 with F1015, F94 with F726, F306 with F567, and 
F491 with F736). Of the patients in whom both NPHP4 mutations were found, only 1 patient shared a mutation 
(F720 with F534) (Table 1). All shared sequence variants were missense. For none of the patients with NPHP4 
sequence variants parental consanguinity was reported. In the 3 families with 2 affected children the 2 recessive 
mutations and 1 single heterozygous sequence variant were present in each of the affected individuals. We also 
detected 6 additional new polymorphisms in NPHP4, that were at least detected once in > 86 healthy control 
individuals (Table 3). We thus identified 23 different novel NPHP4 sequence variants in 26 unrelated families. 
In the 6 families where both NPHP4 mutations were detected (Table 1), 5 of the 8 different mutations detected 
(63%) were truncating mutations (nonsense or frame shift). In contrast, in the 20 families with only one 
heterozygous NPHP4 sequence variant, only 1/20 mutations (5%) was a truncation mutation (c.1839_1840insGA), 
whereas the others were missense sequence variants (Table 1). Thus, the likelihood to detect a truncating mutation 
in patients with two mutated NPHP4 alleles was 12.6 times as high (63% vs. 5%) as in patients with only one 
heterozygous sequence variant. Although the sequence variants identified as single heterozygous missense changes 
were absent from > 86 healthy controls, we cannot exclude that they might represent innocuous polymorphisms. 
The presence or absence of extrarenal manifestation (retinitis pigmentosa, Cogan syndrome, hearing loss, or 
chronic bronchitis) did not correlate with either, i) the position of a mutation within the nephrocystin-
4/nephroretinin sequence; ii) the type of mutation (truncating vs. non-truncating) or; iii) the fact whether both or 
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Table 1.  Twenty-three Novel NPHP4 Sequence Variants Detected in 26 NPH Families With and Without Extrarenal Manifestations 
Family  Origin Number of affecteds 
Age at ESRD 
(yrs) Nucleotide change







Families with both mutated NPHP4 alleles detected   





3 (het, P) 
15 (het, M) +, nd +, nd Chronic bronchitis, nd 






16 (het) + - -
F88         Italy 1 14 c.1462C>T p.Arg488X na 12 (hom) - + -
F617         USA 1 nd c.2608_2617dupTGGAAGCTCA p.Arg870fs na 19 (hom) - + Usher syndrome (hearing loss and RP) 
F456       Italy 1 24 c.2836A>G p.Thr946Ala - 21 (hom) - +  RP
F704 Turkey 2 9, nd c.3149_3150insC p.Gln1050fs na 22 (hom) + + - 
Families with only one single NPHP4 sequence variant detected   
F270          Germany 1 nd c.7G>T p.Asp3Tyr mo 2 (het) nd nd RP
F1015          Germany 1 nd c.7G>T p.Asp3Tyr mo 2 (het) nd nd nd
F94    USA 2 nd c.271T>C p.Phe91Leu mo 3 (het, M) nd nd RP 
F726          Germany 1 nd c.271T>C p.Phe91Leu mo 3 (het) nd nd nd
F719          Serbia 1 12 c.1024C>T p.Arg342Cys ce 9 (het) nd - -
F848          Italy 1 40 c.1880C>T p.Thr627Met - 15 (het) nd + RP
F116           Greece 1 nd 1839_1840insGA p.Lys614fs na 15 (het) - + RP
F534          Germany 1 not yet c.1961C>G p.Ala654Gly ce 16 (het) nd nd nd
F586          Turkey 1 13 c.2213C>T p.Arg735Trp - 17 (het) nd + -
F1142    Belgium 1 nd c.2297A>G p.Gln766Arg mo 17 (het) nd + Color blindness 
F472           Germany 1 not yet c.2327C>G p.Pro776Arg mo 18 (het) - + -
F620          Germany nd nd c.2346C>A p.His782Gln - 18 (het) nd nd nd
F640          Germany 1 nd c.2882G>A p.Arg961His - 21 (het) + + -
F306    Russia 1 14 c.3292G>A p.Ala1098Thr mo, ce 23 (het) nd nd nd 
F567    Germany 1 nd c.3292G>A p.Ala1098Thr mo, ce 23 (het, P) nd nd Cogan syndrome 
F491         Germany 1 nd c.3574C>T p.Arg1192Trp mo 26 (het) nd nd nd
F736         nd 1 nd c.3574C>T p.Arg1192Trp mo 26 (het) nd nd nd
FA2    Australia 1 6 c.3674C>T p.Thr1225Met mo, ce 27 (het, P) + + RP, DD 
F697         Germany 1 nd c.3850C>T p.Arg1284Cys - 28 (het) + + nd
F441    Switzerland 1 nd c.3859C>G p.Gln1287Glu mo 28 (het) + - Hearing loss 
aAll sequence variants were absent from at least 86 healthy control individuals; numbering based on cDNA, Position +1 corresponds to the A of the ATG translation initiation 
codon in the reference sequence NM_015102; ce, amino acid residue conserved in C. elegans; DD, developmental delay; ESRD, end-stage renal disease; M, maternal; mo, 
amino acid residue conserved in mouse; na, not applicable; nd, no data available; P, paternal; RP, retinitis pigmentosa (Senior-Løken syndrome). 
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Table 2. Spectrum of All 35 NPHP4 Sequence Variants Known, Including 23 Novel Sequence Variants 
Detected in this Study 
Type of  
sequence variant Exon Nucleotide change Amino acid change Segregation
a Extrarenal 
manifestationsb Origin Reference 
Nonsense 11 c.1334_1335TC>AA p.Phe445X hom - India (Otto et al., 2002) 
 12 c.1462C>T p.Arg488X hom - Italy Present study 
 16 c.1972C>T p.Arg658X hom RP France (Mollet et al., 2002, Otto et al., 2002) 
 16 c.2044C>T p.Arg682X het, sm - France (Mollet et al., 2002, Otto et al., 2002) 
 18 c.2335C>T p.Glu779X hom RP Turkey (Otto et al., 2002)  
 18 c.2368G>T p.Glu790X hom - Afghanistan (Mollet et al., 2002, Otto et al., 2002) 
 18 c.2377C>T p.Gln793X hom - Italy (Mollet et al., 2002) 
Missense 2 c.7G>T p.Asp3Tyr het, sm (x2) RP (x1) Germany Present study (x2) 
 3 c.271T>C p.Phe91Leu het, sm (x2) RP (x1) USA/Germany Present study (x2) 
 9 c.1024C>T p.Arg342Cys het, sm - Serbia Present study 
 11 c.1405C>T p.Arg469Trp het, sm - Germany Present study 
 15 c.1880C>T p.Thr627Met het, sm RP Italy Present study 
 16 c.1961C>G p.Ala654Gly het, sm (x2) - Germany Present study (x2) 
 17 c.2213C>T p.Arg735Trp het, sm - Turkey Present study 
 17 c.2260G>A p.Gly754Arg het - Germany (Otto et al., 2002)  
 17 c.2297A>G p.Gln766Arg het, sm OA Belgium Present study 
 18 c.2327C>G p.Pro776Arg het, sm - Germany Present study 
 18 c.2346C>A p.His782Gln het, sm - Germany Present study 
 21 c.2836A>G p.Thr946Ala hom RP Italy Present study 
 21 c.2882G>A p.Arg961His het, sm - Germany Present study 
 21 c.2972T>C p.Phe991Ser hom - North Africa (Mollet et al., 2002) 
 23 c.3292G>A p.Ala1098Thr het, sm (x2) Cogan (x1) Russia/Germany Present study (x2) 
 26 c.3574C>T p.Arg1192Trp het, sm (x2) - Germany Present study (x2) 
 27 c.3674C>T p.Thr1225Met het, sm RP Australia Present study 
 28 c.3850C>T p.Arg1284Cys het, sm - Germany Present study 
 28 c.3859C>G p.Gln1287Glu het, sm Loss of Hearing Switzerland Present study 
Deletions 3 c.148delG p.Val79fs het Bronchitis Netherlands Present study 
 15 c.1892-1895delAGAA p.Gln631fs het Bronchitis Netherlands Present study 
 23 c.3272delT p.Val1091fs hom, het, sm OA, Cogan syndrome Germany/France (Mollet et al., 2002, Otto et al., 2002) (x2)
Insertions 15 c.1839_1840insGA p.Lys614fs het, sm RP Greece Present study 
 19 c.2608_2617dupTGGAAGCTCA p.Arg870fs hom Usher syndrome USA Present study 
 22 c.3149_3150insC p.Gln1050fs hom - Turkey Present study 
Splice site IVS15 c.1955+1G>A splice error het - Finland (Otto et al., 2002)  
 IVS16 c.2144-1G>C splice error het - Germany (Otto et al., 2002)  
 IVS24 c.3472+1G>A splice error het - Finland (Otto et al., 2002)  
ahet, heterozygous mutation; hom, homozygous mutation; sm, single mutation; numbering based on cDNA, Position +1 
corresponds to the A of the ATG translation initiation codon in the reference sequence NM_015102; bOA, ophthalmologic 
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Table 3. Spectrum of Polymorphisms 
Type of  
sequence variant Exon Nucleotide change Amino acid change Reference 
Polymorphismsa 2 c.86C>T p.Thr29Met Present study 
 14 c.1631C>G p.Ala544Gly Present study 
 15 c.1852G>A p.Glu618Lys Present study 
 17 c.2219G>A p.Arg740His (Mollet et al., 2002) 
 17 c.2293G>A p.Val765Ile Present study 
 19 c.2542C>T p.Arg848Trp (Mollet et al., 2002)  
 21 c.2818_2822delGCGCAG p.940_941delAlaGln (Mollet et al., 2002)  
aThe term polymorphism was used if the sequence variant was detected in at least 1 out of >172 
chromosomes from healthy control individuals; numbering based on cDNA, Position +1 corresponds to the 






Figure 1. Linear representation of all sequence variants detected in the NPHP4 gene in patients with NPH type 4. Numbering 
based on cDNA, Position +1 corresponds to the A of the ATG translation initiation codon in the reference sequence 
NM_015102. Black and white boxes represent the 30 exons encoding nephrocystin-4/nephroretinin. Positions of novel 
sequence variants detected in this study and of mutations described in the literature are indicated (see also Table 2). Truncating 
mutations are shown in red. The extent of the truncation is shown beneath the exon structure. 
 
DISCUSSION 
By positional cloning we and others have recently identified NPHP4 as a novel gene which, if mutated, causes 
NPH (Mollet et al., 2002, Otto et al., 2002). In order to determine the frequency and the character of mutations in 
NPHP4, we here performed mutational analysis in 250 unrelated NPH patients with and without extrarenal 
manifestations. We detected 23 different novel NPHP4 sequence variants in 26 NPH families. Interestingly, we 
detected homozygous or compound heterozygous mutations of NPHP4 in only 6/250 families (2.4%), whereas we 
detected only one heterozygous NPHP4 sequence variant in 20/250 families (8%). Our data indicate that: i) 
recessive mutations in NPHP4 are a rare cause (2.4%) of nephronophthisis; ii) the presence of a single 
heterozygous NPHP4 sequence variant is 3.3 times more prevalent than the presence of 2 recessive NPHP4 
mutations; iii) a genotype/phenotype correlation was not detected for the presence or absence of extrarenal 
manifestation; iv) and, there must exist further genes causing nephronophthisis, since in 224/250 (90%) patients no 
mutation in either of the four NPH genes was detected. 
When examining a total of 515 unrelated NPH patients with and without extrarenal manifestations we had 
detected homozygous NPHP1 deletions in 130 patients (25.2%) (Hoefele et al., unpublished). In addition, we 
found a combination of a heterozygous NPHP1 deletion and a heterozygous NPHP1 point mutation in 10/515 
patients (2%) (Hoefele et al., unpublished). This indicates that in about 27% of all patients with NPH the disease is 
caused by mutations in NPHP1 and thus represents nephronophthisis type 1. In this study we demonstrate that two 
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recessive mutations in NPHP4 occur in only 2.4% of all NPH cases, thereby showing that NPH type 4 represents a 
rare cause of NPH with and without extrarenal manifestations. This finding supports the concept that NPH is a 
disorder that shows extensive genetic locus heterogeneity, and that most likely many additional genes are involved 
(Mollet et al., 2002). The finding that in 224/250 (90%) patients no NPHP4 mutation was detected, further 
supports the notion there must exist additional genes causing NPH. All 23 NPHP4 sequence variants identified in 
this study have not been described before (Mollet et al., 2002, Otto et al., 2002) and are therefore novel. We thus 
expanded the spectrum of distinct NPHP4 sequence variants from 13 to a total of 35 (Table 2, Fig. 1). Although 
the sequence variants were distributed over all 30 exons of NPHP4, there was a propensity towards the C-terminal 
part of the protein, since 25/35 (71%) of all sequence variants identified in this study are located within exons 16-
30 (Table 2). 
We here observed the finding that the presence of a single heterozygous NPHP4 sequence variant was 3.3 times 
more prevalent (20/250) than the presence of two NPHP4 mutations (6/250). This is reminiscent of our recent 
finding in patients with NPH type 3, where 3/9 patients (33%) showed two mutations in NPHP3, whereas 6/9 
patients (67%) had only a single NPHP3 sequence variant (Olbrich et al., 2003). The finding that a single 
heterozygous NPHP4 sequence variant was 3.3 times more prevalent than a two recessive NPHP4 mutations may 
be interpreted in a variety of ways: 
First, a second mutation may have been missed for technical reasons. We deem this possibility very unlikely, 
since we employed the optimal method for mutation detection: direct exon sequencing from both strands, yielding 
excellent sequence quality. In addition, we evaluated sequences by two independent computer programs 
(SequencherTM and Mutation SurveyorTM) and by two independent examiners, which in our experience leads to 
very sensitive mutation detection. Second, a mutation might be located in a non-exonic region. Although this 
possibility cannot be ruled out with certainty, this is a rare finding. It would therefore not explain the 3.3 fold 
higher prevalence of patients with a single sequence variant versus patients in whom both mutated alleles are 
detected. Third, another potential explanation for the high number of single sequence variants found in NPHP3 and 
NPHP4 would be the possibility of a dominant effect of these mutations. However, there is no evidence of any 
clinical signs or symptoms of NPH or extrarenal manifestations in the parents of the 515 NPH patients from our 
total cohort or in the literature. Fourth, it may well be possible that single heterozygous sequence variants may 
represent innocuous polymorphisms. Finally, it cannot be excluded altogether, that some of the single 
heterozygous sequence variants observed may be part of digenic or oligogenic mutations in other NPH-causing 
genes, as has been described for the related disease Bardet-Biedl syndrome (Badano et al., 2003). 
It is known that in about 10% of all patients with NPH there is an association with retinitis pigmentosa (SLS) 
(Caridi et al., 1998). However, to date no correlation has been described for the presence or absence of extrarenal 
involvement in NPH with respect to the gene involved or with respect to specific allelic mutations. Similarly, in 
this study we did not detect any evidence for a genotype/phenotype relationship regarding extrarenal 
manifestations, since extrarenal manifestations (retinitis pigmentosa, Cogan syndrome, hearing loss, or chronic 
bronchitis) did not correlate with either, i) the position of a mutation within the nephrocystin-4/nephroretinin 
sequence, ii) the type of mutation (truncating vs. non-truncating) or, iii) the fact whether both or only one NPHP4 
sequence variant was found (Table 1). Nevertheless, further inter- and intrafamilial studies on a higher number of 
patients with NPHP4 mutations might yield more information on genotype-phenotype correlations in NPH. 
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